▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2428 by analyst upside · 2026-06-27
PACS
PACS Group, Inc.
Healthcare · Market Cap $7B · P/E 27.0x
ANALYST PRICE TARGET
+18.6%
implied upside to consensus target
Current Price $41.89
Consensus Target $49.67
Bull Target $52.0
Bear Target $47.0
Analysts Covering 6
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
4
Hold
0
Sell
0
52-Week Low $7.5
52-Week High $43.08
YTD Return +6.0%
FUNDAMENTALS
Market Cap $7B
P/E Ratio (TTM) 27.0x
Forward P/E 16.7x
EPS (TTM) $1.55
PEG Ratio 1.14
Dividend Yield N/A
Revenue (TTM) $5.4B
Profit Margin 4.5%
52-WEEK RANGE
52-Week Low $7.5
52-Week High $43.08
Current Price $41.89
Bear Target $47.0
Bull Target $52.0
● Now $41.89 ● Target $49.67
TRADING DATA
Avg Volume 859K
YTD Return +6.0%
Analyst Count 6
Consensus Buy
Upside to Target +18.6%
Last Updated 2026-06-27

ANALYST SUMMARY

PACS Group, Inc. (PACS) is currently trading at $41.89 with a Wall Street consensus price target of $49.67, implying potential upside of 18.6% over the next 12 months. 6 analysts currently cover PACS, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $52.0, while the most cautious has a target of $47.0.

PACS operates in the Healthcare sector with a market capitalisation of $7B. The stock is up 6.0% year-to-date and is currently trading near the upper end of its 52-week range of $7.5 – $43.08.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

HQY +30.6%
HealthEquity, Inc.
$7B · P/E 31.3x · Buy
ATR +27.3%
AptarGroup, Inc.
$8B · P/E 21.6x · Buy
QGEN +11.6%
Qiagen N.V.
$8B · P/E 20.1x · Buy
CHE -3.6%
Chemed Corporation
$6B · P/E 24.7x · Hold
SHC +16.4%
Sotera Health Company
$5B · P/E 42.4x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for PACS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Truist Securities — Reiterated
Buy → Buy 2026-05-18 Building track record
Oppenheimer — Reiterated
Outperform → Outperform 2026-05-13 14% win rate (7 calls)
UBS — Reiterated
Buy → Buy 2026-03-04 33% win rate (6 calls)
Oppenheimer — Reiterated
Outperform → Outperform 2026-03-04 14% win rate (7 calls)
RBC Capital — Reiterated
Outperform → Outperform 2026-02-27 Building track record
RBC Capital — Reiterated
Outperform → Outperform 2025-11-20 Building track record
Macquarie — Reiterated
Outperform → Outperform 2025-01-06 Building track record
Truist Securities — Reiterated
Buy → Buy 2025-01-06 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
70
out of 100
Coverage depth
15/30
Consensus clarity
28/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →